BioCryst Pharmaceuticals Inc.

2 days ago · schaeffersresearch.com

After its most recent pullback, biopharmaceutical stock BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) bounced off the $8 level and has now reclaimed the 320-day moving average -- both of which have been key lines of pressure and support.

4 days ago · marketbeat.com

BioCryst Pharmaceuticals NASDAQ: BCRX is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event.

8 days ago · seekingalpha.com

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

12 days ago · seekingalpha.com

BioCryst Pharmaceuticals, Inc.'s shares remain under pressure. At the same time, Orladeyo revenue increased 6.7% QoQ to $158.2 million in the second quarter. BioCryst's royalty financing obligations declined from $465.7 million at the end of Q4 2025 to $426.8 million at the end of June.

23 days ago · globenewswire.com

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET.

23 days ago · zacks.com

Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

26 days ago · zacks.com

The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

27 days ago · cnbc.com

BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize biotech companies are increasingly stepping in to develop and acquire rare disease drugs.

1 month ago · defenseworld.net

Assenagon Asset Management S.A. boosted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 51.6% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 353,044 shares of the biotechnology company's stock after purchasing an additional 120,097 shares during the period.

1 month ago · zacks.com

The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.